IL127142A0 - Immune cells having predefined biological specificity - Google Patents

Immune cells having predefined biological specificity

Info

Publication number
IL127142A0
IL127142A0 IL12714298A IL12714298A IL127142A0 IL 127142 A0 IL127142 A0 IL 127142A0 IL 12714298 A IL12714298 A IL 12714298A IL 12714298 A IL12714298 A IL 12714298A IL 127142 A0 IL127142 A0 IL 127142A0
Authority
IL
Israel
Prior art keywords
immune cells
biological specificity
predefined biological
predefined
specificity
Prior art date
Application number
IL12714298A
Original Assignee
Yeda Res & Dev
Reinder L H Bolhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Reinder L H Bolhuis filed Critical Yeda Res & Dev
Priority to IL12714298A priority Critical patent/IL127142A0/en
Publication of IL127142A0 publication Critical patent/IL127142A0/en
Priority to AU12927/00A priority patent/AU1292700A/en
Priority to PCT/IL1999/000622 priority patent/WO2000031239A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL12714298A 1998-11-19 1998-11-19 Immune cells having predefined biological specificity IL127142A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL12714298A IL127142A0 (en) 1998-11-19 1998-11-19 Immune cells having predefined biological specificity
AU12927/00A AU1292700A (en) 1998-11-19 1999-11-18 Immune cells having predefined biological specificity, comprising chimeric t cell receptor
PCT/IL1999/000622 WO2000031239A1 (en) 1998-11-19 1999-11-18 Immune cells having predefined biological specificity, comprising chimeric t cell receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12714298A IL127142A0 (en) 1998-11-19 1998-11-19 Immune cells having predefined biological specificity

Publications (1)

Publication Number Publication Date
IL127142A0 true IL127142A0 (en) 1999-09-22

Family

ID=11072157

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12714298A IL127142A0 (en) 1998-11-19 1998-11-19 Immune cells having predefined biological specificity

Country Status (3)

Country Link
AU (1) AU1292700A (en)
IL (1) IL127142A0 (en)
WO (1) WO2000031239A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388942B1 (en) * 2000-07-08 2003-06-25 한화석유화학 주식회사 A Single Chain Variable Fragment of an Antibody for Protein Expressed on Cell Surface of Human Cortical Thymocyte and Leukemic Cell
CA2416794A1 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
EP1334188B1 (en) 2000-11-07 2006-08-30 City of Hope Cd19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
DE10259713A1 (en) * 2002-12-19 2004-07-08 Johannes-Gutenberg-Universität Mainz Process for the stabilization of expression and improvement of the specific effector function of single chain antigen-recognizing genetic constructs (scARC) and corresponding mutated MDM2 protein specific scT cell receptors
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
CA2634292A1 (en) * 2005-12-20 2007-06-28 Erasmus University Medical Center Rotterdam Apoptosis-inducing protein complexes and therapeutic use thereof
EP3097923B1 (en) 2007-01-31 2022-07-27 Yeda Research And Development Co., Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
ES2686424T5 (en) * 2010-05-04 2023-03-27 Yeda Res & Dev Redirected allogeneic cell immunotherapy
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP2755997B1 (en) * 2011-09-15 2018-07-04 The United States of America, as represented by The Secretary, Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
AU2012316859A1 (en) * 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
WO2013105856A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
JP6389166B2 (en) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ Anti-B7-H6 antibodies, fusion proteins, and methods of using them
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CA2982452A1 (en) 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017123808A1 (en) 2016-01-15 2017-07-20 The J. David Gladstone Institutes Methods of treating disease by metabolic control of t-cell differentiation
US11730761B2 (en) 2016-02-18 2023-08-22 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN110198954A (en) 2017-01-13 2019-09-03 艾吉纳斯公司 T cell receptor and its application method in conjunction with NY-ESO-1
CN111278854A (en) 2017-09-04 2020-06-12 艾吉纳斯公司 T cell receptors that bind Mixed Lineage Leukemia (MLL) -specific phosphopeptides and methods of use thereof
CN107881185A (en) * 2017-11-21 2018-04-06 重庆天科雅生物科技有限公司 A kind of single-stranded TCR carrier Ts and single-stranded TCR T cells production technology
JP2024507929A (en) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド Recombinant vectors containing polycistronic expression cassettes and methods for their use
WO2023047089A1 (en) 2021-09-21 2023-03-30 Oslo Universitetssykehus Hf Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
EP0910409A4 (en) * 1996-03-05 2003-03-19 Scripps Research Inst Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens

Also Published As

Publication number Publication date
AU1292700A (en) 2000-06-13
WO2000031239A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
IL127142A0 (en) Immune cells having predefined biological specificity
DE60026352D1 (en) Biosensor
IL124903A0 (en) An enzyme biosensor
EP1182450A4 (en) Biosensor
IL129890A0 (en) Modified bioreactor
GB9928968D0 (en) Enzyme
GB9808145D0 (en) Assay
EP1156105A4 (en) Novel enzyme
HK1055443A1 (en) Novel enzyme
GB9906245D0 (en) Enzyme
GB9818931D0 (en) Photobioreactor
IL120445A0 (en) Biosensor for cells
GB9803156D0 (en) Assay
GB9821198D0 (en) Enzyme
GB9820817D0 (en) Enzyme
EP0986747A4 (en) Improved biosensor
GB9924634D0 (en) Enzyme
PL345071A1 (en) Novel biocontrol agents
GB9908458D0 (en) Enzyme
EP1012248A4 (en) Novel thermophilic polymerase iii holoenzyme
GB9810997D0 (en) Genes & enzymes
GB9823882D0 (en) Enzyme
GB9815404D0 (en) Enzyme
GB9826777D0 (en) Enzyme
GB9828603D0 (en) Enzyme